MY186779A - Nucleic acid derivative having immunostimulatory activity - Google Patents
Nucleic acid derivative having immunostimulatory activityInfo
- Publication number
- MY186779A MY186779A MYPI2019004986A MYPI2019004986A MY186779A MY 186779 A MY186779 A MY 186779A MY PI2019004986 A MYPI2019004986 A MY PI2019004986A MY PI2019004986 A MYPI2019004986 A MY PI2019004986A MY 186779 A MY186779 A MY 186779A
- Authority
- MY
- Malaysia
- Prior art keywords
- nucleic acid
- acid derivative
- strand
- immunostimulatory activity
- nucleotides
- Prior art date
Links
- 230000003308 immunostimulating effect Effects 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 5
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2017/013025 WO2018179172A1 (ja) | 2017-03-29 | 2017-03-29 | 免疫賦活活性を有する核酸誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY186779A true MY186779A (en) | 2021-08-19 |
Family
ID=63674710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2019004986A MY186779A (en) | 2017-03-29 | 2017-03-29 | Nucleic acid derivative having immunostimulatory activity |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JP6611298B2 (ja) |
| BR (1) | BR112019019177B8 (ja) |
| IL (1) | IL268983B2 (ja) |
| MY (1) | MY186779A (ja) |
| PH (1) | PH12019502063A1 (ja) |
| SG (1) | SG11201908059YA (ja) |
| WO (1) | WO2018179172A1 (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR114990A1 (es) * | 2017-11-02 | 2020-11-18 | Alios Biopharma Inc | Constructos de oligonucleótidos y usos de los mismos |
| JP7584410B2 (ja) * | 2019-06-03 | 2024-11-15 | 塩野義製薬株式会社 | 二分岐脂質結合オリゴヌクレオチドの製造方法及び中間体 |
| EP3892260A1 (en) * | 2020-04-10 | 2021-10-13 | Bayer Animal Health GmbH | Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids |
| CN116322779A (zh) * | 2020-09-10 | 2023-06-23 | 联合免疫股份有限公司 | 复合体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2314693A3 (en) * | 1999-08-13 | 2012-11-28 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| WO2003066649A1 (en) * | 2002-02-04 | 2003-08-14 | Biomira Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
| GB0605247D0 (en) * | 2006-03-15 | 2006-04-26 | Chiron Srl | Compositions and methods for immunisation |
| MX2011002267A (es) * | 2008-08-28 | 2011-03-30 | Glaxosmithkline Biolog Sa | Vacuna. |
| BRPI0922561A2 (pt) * | 2008-12-09 | 2020-08-11 | Pfizer Vaccines Llc | vacina de peptídeo de ch3 da ige. |
| JP6375289B2 (ja) * | 2012-04-05 | 2018-08-15 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫刺激組成物およびその使用方法 |
| JP6482475B2 (ja) * | 2014-01-07 | 2019-03-13 | レナセラピューティクス株式会社 | アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド |
-
2017
- 2017-03-29 SG SG11201908059Y patent/SG11201908059YA/en unknown
- 2017-03-29 IL IL268983A patent/IL268983B2/en unknown
- 2017-03-29 BR BR112019019177A patent/BR112019019177B8/pt active IP Right Grant
- 2017-03-29 MY MYPI2019004986A patent/MY186779A/en unknown
- 2017-03-29 JP JP2019508453A patent/JP6611298B2/ja active Active
- 2017-03-29 WO PCT/JP2017/013025 patent/WO2018179172A1/ja not_active Ceased
-
2019
- 2019-09-11 PH PH12019502063A patent/PH12019502063A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018179172A1 (ja) | 2018-10-04 |
| IL268983B2 (en) | 2024-07-01 |
| IL268983B1 (en) | 2024-03-01 |
| PH12019502063A1 (en) | 2020-09-28 |
| BR112019019177B1 (pt) | 2021-05-11 |
| BR112019019177A2 (pt) | 2020-04-14 |
| JP6611298B2 (ja) | 2019-11-27 |
| JPWO2018179172A1 (ja) | 2020-02-06 |
| BR112019019177B8 (pt) | 2022-09-13 |
| IL268983A (en) | 2019-10-31 |
| SG11201908059YA (en) | 2019-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX374553B (es) | Derivado de ácido nucleico que tiene actividad inmunoestimuladora. | |
| CY1123289T1 (el) | Ενωσεις ολιγονουκλεοτιδιων για τη στοχευση του huntingtin mrna | |
| MX2010004452A (es) | Acido ribonucleico de doble cadena modificado con lipidos que tienen un potente efecto de interferencia de acido ribonucleico. | |
| JP2016526529A5 (ja) | ||
| JP2015142558A5 (ja) | ||
| WO2016140726A3 (en) | Triggered assembly of metafluorophores | |
| WO2016106401A3 (en) | Rna agents for p21 gene modulation | |
| EA201791820A1 (ru) | Олигонуклеотидная терапия врожденного амавроза лебера | |
| AU2014219019A8 (en) | Short interfering nucleic acid (siNA) molecules containing a 2' internucleoside linkage | |
| BR112013005872A2 (pt) | compostos, composição farmacêutica e respectivos usos | |
| MX344972B (es) | Oligonucleotidos inmunoestimulantes. | |
| BR112015024764A2 (pt) | oligonucleotídeos de tgf-beta modificados | |
| PH12019502063A1 (en) | Nucleic acid derivative having immunostimulatory activity | |
| EP4585686A3 (en) | Modified double-stranded rna agents | |
| NZ563845A (en) | RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic | |
| SG10201705285SA (en) | Antisense oligonucleotides | |
| HK1221978A1 (zh) | Tmprss6 irna组合物及其使用方法 | |
| MY196912A (en) | Short pendant arm linkers for nucleotides in sequencing applications | |
| AR100946A1 (es) | Composiciones y métodos para regular la expresión génica por medio de la interferencia de arn | |
| PE20211238A1 (es) | Tratamiento antisentido del sindrome de angelman | |
| EA201791986A1 (ru) | Олигонуклеотиды, соответствующие экзону 73 гена col7a1, для терапии буллезного эпидермолиза | |
| WO2017007886A3 (en) | Compositions for inhibiting dux4 gene expression and uses thereof | |
| AR083445A1 (es) | siARN CONTRA LA FIBROSIS | |
| MX377713B (es) | Moleculas de ácido ribonucleico pequeño de interferencia especifico de notch 1. | |
| JP2016108250A5 (ja) |